Experience with lymphatic mapping in breast cancer using isosulfan blue dye

被引:8
作者
Ratanawichitrasin, A
Levy, L
Myles, J
Crowe, JP
机构
[1] Cleveland Clin Breast Ctr, Dept Gen Surg, Cleveland, OH USA
[2] Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA
来源
JOURNAL OF WOMENS HEALTH | 1998年 / 7卷 / 07期
关键词
D O I
10.1089/jwh.1998.7.873
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Sentinel (first tumor-draining) lymph node (SLN) biopsy directed by the blue dye technique may be as accurate as complete axillary lymph node dissection (ALND) in determining whether breast cancer has metastasized to the lymph nodes and may have fewer surgical complications because it is less invasive. Breast cancer patients scheduled for ALND between February and June 1997 who did not have prior axillary surgery, prior radiation therapy, or preoperative chemotherapy were included. Isosulfan blue dye was injected around the primary tumor or the biopsy cavity just before ALND. Operations were performed in a tertiary breast center by two breast surgeons who did not have experience with the technique before this study. The results of blue stained nodes were compared to those of the ALND. Blue-stained nodes were identified in 35 of 40 patients (88%), and the results were concordant with ALND in 33 of 35 (94%), 7 patients were concordant for positive results and 26 for negative results. We identified SLNs in patients whose cancers were either in the medial or lateral halves of the breast. Average time for SLN dissection was 19 +/- 9 minutes, and there were no complications. The diagnostic accuracy of the isosulfan blue dye technique for SLN biopsy, 94%, is high enough to warrant further research. The lack of complications and the short time needed to perform the technique are attractive features. Broader experience with the technique is required to evaluate the reliability and reproducibility of this method.
引用
收藏
页码:873 / 877
页数:5
相关论文
共 8 条
[1]   Lymphatic mapping and sentinel node biopsy in the patient with breast cancer [J].
Albertini, JJ ;
Lyman, GH ;
Cox, C ;
Yeatman, T ;
Balducci, L ;
Ku, NN ;
Shivers, S ;
Berman, C ;
Wells, K ;
Rapaport, D ;
Shons, A ;
Horton, J ;
Greenberg, H ;
Nicosia, S ;
Clark, R ;
Cantor, A ;
Reintgen, DS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (22) :1818-1822
[2]   Prognostic significance of occult lymph node metastases in node-negative breast cancer [J].
Clare, SE ;
Sener, SF ;
Wilkens, W ;
Goldschmidt, R ;
Merkel, D ;
Winchester, DJ .
ANNALS OF SURGICAL ONCOLOGY, 1997, 4 (06) :447-451
[3]   LYMPHATIC MAPPING AND SENTINEL LYMPHADENECTOMY FOR BREAST-CANCER [J].
GIULIANO, AE ;
KIRGAN, DM ;
GUENTHER, JM ;
MORTON, DL .
ANNALS OF SURGERY, 1994, 220 (03) :391-401
[4]  
OLLILA DW, 1998, BREAST DIS, V8, P297
[5]  
PICKREN JW, 1961, CANCER-AM CANCER SOC, V14, P1266, DOI 10.1002/1097-0142(196111/12)14:6<1266::AID-CNCR2820140617>3.0.CO
[6]  
2-9
[7]  
STATMAN RC, 1996, P AN M AM SOC CLIN, V15, P125
[8]   Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes [J].
Veronesi, U ;
Paganelli, G ;
Galimberti, V ;
Viale, G ;
Zurrida, S ;
Bedoni, M ;
Costa, A ;
deCicco, C ;
Geraghty, JG ;
Luini, A ;
Sacchini, V ;
Veronesi, P .
LANCET, 1997, 349 (9069) :1864-1867